[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behcet-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behcet-syndrome":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100576067","phase-3-randomized-controlled-multicenter-study-comparing-steroid-therapy-plus-anticoagulants-to-steroid-therapy-alone-in-deep-venous-thrombosis-of-behets-syndrome-100576067",false,"NCT06780462","Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome","ACTOR","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Diagnosis of BS according to the international criteria\n3. First or recurrent deep venous thrombosis diagnosed on imaging (venous ultrasonography , and\u002For Angio CT scan and\u002For angio MRI)\n4. Written inform consent\n5. Women of childbearing potential (WOCBP) are required to have a negative pregnancy test before treatment and must agree to maintain during treatment highly effective contraception (ie, abstinence, combined estrogen- and progestogen- containing hormonal contraception, ovulation inhibitors (Oral, Intravaginal, Transdermal); Progestogen-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable); Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner).\n6. Affiliation to a social security system. Patients affiliated to universal medical coverage (CMU) are eligible for the study\n\nExclusion Criteria:\n\n1. Clinical condition, other than venous thrombosis, requiring anticoagulation (e.g. atrial fibrillation…)\n2. Active bleeding or high risk for bleeding contraindicating treatment with anticoagulants\n3. Isolated superficial thrombosis without concomitant deep venous thrombosis.\n4. Pregnancy or lactation\n5. Have been taking an oral daily dose of a glucocorticoid of more than 20 mg prednisone equivalent for more than 6 weeks continuously prior to the inclusion visit or taking more than 4000 mg methylprednisolone 4 weeks prior to the inclusion visit\n6. Have been taking anti-coagulation therapy for more than 4 weeks prior to inclusion\n7. Severe chronic renal (creatinine clearance \\\u003C30ml\u002Fmin\u002F1,73m2) or liver insufficiency associated with coagulopathy\n8. Platelet count \\\u003C 50 x 103\u002Fmm3\n9. Change in the treatment with systemic biologic therapy or immunosuppressant therapy dose 1 month prior to inclusion visit.\n10. Contraindication to investigational medicinal products (Corticosteroids and direct oral anticoagulant (Rivaroxaban))\n11. Participation to another interventional clinical trial or being in the exclusion period at the end of a previous study","ALL","18 Years",{"count":19,"type":20},134,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.\n\nPost Thrombotic Syndrome (PTS) is frequent especially with recurrent episodes of deep vein thrombosis and may result in leg ulcers that are very difficult to treat. Vascular involvement is a major cause of morbidity and mortality among BS patients. However, one of the most controversial issues regarding the management of BS is whether DVT should be treated with anticoagulants. Moreover, use of anticoagulants exposes patients to serious bleeding, especially in those who presents simultaneous arterial aneurysms. However, many physicians are still using anticoagulants. This is the first prospective, randomized study assessing benefits of corticosteroids associated with anticoagulant compared to that of corticosteroids alone in DVT in BS patients. It will validate or not the use of anticoagulants in those situations. It will allow a direct comparison of the safety profile of those two schemes of treatment.",[26],"Behcet Syndrome","RECRUITING","2026-04-22",{"date":30,"type":31},"2026-04-23","ACTUAL",{"date":33,"type":31},"2025-06-24",{"date":35,"type":20},"2028-06-24",{"name":37,"class":38},"Assistance Publique - Hôpitaux de Paris","OTHER",17,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100454682","autoinflammatory-disease-alliance-registry-aida-100454682","NCT05200715","AutoInflammatory Disease Alliance Registry (AIDA)","Development of an International Multicenter Registry of Patients With Monogenic and Polygenic Autoinflammatory Diseases Aimed at Clinical and Therapeutical Data Collection and Analysis","AIDA","Inclusion Criteria:\n\n* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;\n* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and\u002For classification criteria;\n* to be diagnosed with undifferentiated systemic AID;\n* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;\n* to be diagnosed with anterior or posterior non-infectious scleritis;\n* to be diagnosed with spondyloarthritis according to ASAS and\u002For New York criteria;\n* to be diagnosed with Castleman disease;\n\nExclusion Criteria:\n\n\\- informed consent\u002Fassent not provided by the patient and\u002For his\u002Fher legal representative.",{"count":49,"type":20},3500,"10 Years","OBSERVATIONAL","Autoinflammatory diseases (AID) are clinical entities characterized by recurrent inflammatory attacks in absence of infection, neoplasm or deregulation of the adaptive immune system. Among them, hereditary periodic syndromes, also known as monogenic AID, represent the prototype of this disease group, caused by mutations in genes involved in the regulation of innate immunity, inflammation and cell death. Based on recent experimental acquisitions in the field of monogenic AID, several immunologic disorders have been reclassified as polygenic\u002Fmultifactorial AID, sharing pathogenetic and clinical features with hereditary periodic fevers. This has paved the way to new treatment targets for patients suffering from rare diseases of unknown origin, including Behçet's disease, Still disease, Schnitzler's disease, PFAPA (periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis) syndrome, chronic recurrent multifocal osteomyelitis (CRMO), non-infectious uveitis and scleritis. Gathering information on such rare conditions is made difficult by the small number of patients, along with the difficulty of obtaining an accurate diagnosis in non-specialized clinical settings.\n\nIn this context, the AIDA project promotes international collaboration among clinical centres to develop a permanent registry aimed at collecting demographic, genetic, clinical and therapeutic data of patients affected by monogenic and polygenic AID, in order to expand the current knowledge of these rare conditions.",[54,55,26,56,57,58,59,60,61,62,63],"Hereditary Autoinflammatory Diseases","Schnitzler Syndrome","PFAPA Syndrome","Still Disease","Autoinflammatory Syndrome, Unspecified","Uveitis","Scleritis","Vexas Syndrome","Spondyloarthritis (SpA)","Castleman Disease","2025-07-07",{"date":66,"type":31},"2025-07-10",{"date":68,"type":31},"2020-08-06",{"date":70,"type":20},"2030-08-06",{"name":72,"class":38},"University of Siena",112]